MUC-1 (CA 15-3 antigen) as a highly reliable predictor of response to EGFR inhibitors in patients with bronchioloalveolar carcinoma: an experience on 26 patients.
Int J Biol Markers
; 22(4): 307-11, 2007.
Article
en En
| MEDLINE
| ID: mdl-18161663
ABSTRACT
BACKGROUND:
Bronchioloalveolar carcinoma (BAC) is a histological subtype of non-small cell lung cancer (NSCLC), particularly of adenocarcinoma. Given its multifocality and the poor activity of chemotherapy, there is no established treatment for BAC, although promising results have been achieved with inhibitors of the epidermal growth factor receptor (EGFR). No tumor marker has been validated in the diagnosis and follow-up of lung cancer, in particular to predict the outcome of treatment with EGFR inhibitors.PURPOSE:
As CA 15-3 antigen serum levels are reported to be pathologically abnormal in adenocarcinoma of the lung, we chose this tumor marker to monitor treatment with EGFR inhibitors of patients affected by adenocarcinoma with BAC features or pure BAC. PATIENTS ANDMETHODS:
We collected data from 26 consecutive Caucasian patients with BAC, mostly women and never smokers, who received EGFR inhibitors.RESULTS:
We noticed that all patients with normal CA 15-3 serum levels at baseline (15/26, 57.7%) showed a response to EGFR inhibitors, whereas all patients with abnormal CA 15-3 serum levels (11/26, 42.3%) did not.CONCLUSION:
Our data suggest that CA 15-3 levels might be a predictive factor for the response to EGFR inhibitors in patients with BAC.
Search on Google
Banco de datos:
MEDLINE
Asunto principal:
Biomarcadores de Tumor
/
Regulación Neoplásica de la Expresión Génica
/
Carcinoma de Pulmón de Células no Pequeñas
/
Adenocarcinoma Bronquioloalveolar
/
Mucina-1
/
Receptores ErbB
/
Neoplasias Pulmonares
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Año:
2007
Tipo del documento:
Article